

Regional Differences in the Inhibition of Mouse In Vivo [³H]Ro 15-1788 Binding Reflect Selectivity for α_1 versus α_2 and α_3 Subunit-Containing GABA_A Receptors

John R. Atack, Ph.D., Alison J. Smith, B.Sc., Frances Emms, B.Sc., and Ruth M. McKernan, Ph.D.

The benzodiazepines flunitrazepam, diazepam, and Ro 15-1788 and the β -carboline DMCM bind with equivalent affinity to the benzodiazepine binding site of GABA_A receptors containing different α subunits (i.e., α_1 , α_2 , α_3 , or α_5); whereas, the triazolopyridazine CL 218,872 and imidazopyridine zolpidem have higher affinity for α_1 subunit-containing GABA_A receptors. In the present study, the *in vivo* binding of [³H]Ro 15-1788 in mouse cerebellum and spinal cord was used to establish the occupancy of the benzodiazepine binding site of GABA_A receptors containing primarily α_1 and α_2/α_3 subunits, respectively. Thus, the nonselective compounds flunitrazepam, diazepam, and DMCM all produced a similar inhibition of binding in cerebellum and spinal cord (respective ID₅₀ values of 0.2 to

0.3 mg/kg, 2 mg/kg, and 10 mg/kg IP); whereas, the α_1 selective compounds CL 218,872 and zolpidem were more potent at inhibiting [³H]Ro 15-1788 binding in the cerebellum (ID₅₀ values 4.5 mg/kg and 10 mg/kg IP) compared to the spinal cord (ID₅₀ values 12 mg/kg and >30 mg/kg IP). Thus, the reduction of *in vivo* [³H]Ro 15-1788 binding in tissues containing α_1 and α_2/α_3 receptor populations reflects the *in vitro* affinities of subtype selective compounds and should help to interpret the behavioral profile of such compounds.

[*Neuropsychopharmacology* 20:255–262, 1999]

© 1999 American College of Neuropsychopharmacology.
Published by Elsevier Science Inc.

KEY WORDS: Ro 15-1788; Benzodiazepine; *In vivo* binding; GABA_A receptors

GABA is the major inhibitory neurotransmitter within the CNS (Rabow et al. 1995). Its actions are mediated via the ionotropic GABA_A and GABA_C receptors and the metabotropic GABA_B receptor. To date, sixteen ionotropic GABA receptor subunit genes have been identified (α_{1-6} , β_{1-3} , γ_{1-3} , δ , ρ_{1-2} , and ϵ), with further diversity

being introduced by the presence of alternatively spliced forms of certain of these subunits (Lüddens et al. 1995; Stephenson 1995; Davies et al. 1997; Whiting et al. 1997). Of these subunit genes, the ρ_{1-2} subunits constitute the GABA_C receptor, which is found in the retina and arguably various regions of the brain (Johnston 1996); whereas, the GABA_A receptor is generally considered to be a pentamer of α , β , and γ subunits, with the role of the δ and ϵ subunits being poorly understood (Lüddens et al. 1995; Stephenson 1995; McKernan and Whiting 1996; Davies et al. 1997; Whiting et al. 1997).

The GABA_A receptor and its molecular structure and pharmacology has attracted considerable attention in view of it being the site of action of a number of compounds that can affect receptor function (i.e., chloride ion flux) either directly, by binding at the GABA site or

From the Merck Sharp & Dohme Research Laboratories, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex, UK.

Address correspondence to: Dr. John R. Atack, Neuroscience Research Centre, Merck Sharp & Dohme Research Laboratories, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, UK.

Received 23 January 1998; revised 22 April 1998; accepted 20 May 1998.

within the ion channel, or indirectly, by binding to allosteric modulatory sites. Included in this latter class of compounds are the benzodiazepines, neurosteroids, barbiturates (such as pentobarbital), the anticonvulsant loreclezole, and some anesthetics (for example, etomidate and alphaxalone) (Sieghart 1995). Of these allosteric sites, the binding site for benzodiazepines has been most intensively studied, because of its clinical relevance in mediating the anxiolytic, anticonvulsant, sedative-hypnotic, and muscle relaxant effects of such drugs as chlordiazepoxide, diazepam, and flunitrazepam.

A number of pharmacologically distinct benzodiazepine binding sites can be identified on the basis of their affinities for the "classical" benzodiazepines, such as diazepam and flunitrazepam, as well as the atypical benzodiazepines 2-oxoquazepam and Ro 15-4513 and non-benzodiazepines, such as the triazolopyridazine CL 218,872, the imidazopyridine zolpidem, the β -carboline methyl β -carboline-3-carboxylate (β -CCM) and the cyclopyrrolones zopiclone and suriclone (Lüddens et al. 1995). The characterization of various cloned GABA_A receptors expressed in either *Xenopus* oocytes or mammalian cells has defined the molecular basis of this pharmacological diversity (Rabow et al. 1995; Sieghart 1995). Hence, the benzodiazepine binding site requires the presence of an α and a γ subunit, with the pharmacology of the binding site of physiologically relevant GABA_A receptors being determined largely by the type of α subunit present (Rabow et al. 1995; Sieghart 1995; McKernan and Whiting 1996).

More specifically, the α_4 or α_6 subunit renders GABA_A receptors insensitive to "classical" benzodiazepines, such as diazepam. With respect to diazepam-sensitive GABA_A receptors, the presence of an α_1 subunit confers high affinity for CL 218,872 and zolpidem; whereas, α_5 subunit-containing GABA_A receptors have essentially no affinity for zolpidem. Receptors containing either an α_2 or α_3 subunit possess an intermediate affinity for zolpidem (Lüddens et al. 1995; Rabow et al. 1995; Sieghart 1995; McKernan and Whiting 1996). This pharmacological diversity is further exacerbated by the neuroanatomical heterogeneity of the distribution of these different GABA_A receptor subtypes. Thus, although the cortex and hippocampus contain α_1 , α_2 , α_3 , α_4 , and α_5 subunits, more restricted localizations are found in the cerebellum (primarily α_1 and α_6), spinal cord (primarily α_2 and α_3), and thalamus (primarily α_1 and α_4) (Wisden et al. 1991, 1992; Fritschy and Mohler 1995). Consistent with this anatomical distribution, in vitro pharmacological analysis of cerebellum and spinal cord GABA_A receptors (Villiger 1984; Watanabe et al. 1985; Langer and Arbilla 1988; Benavides et al. 1988, 1992) suggests that the benzodiazepine pharmacology of the cerebellum and spinal cord are dictated largely by the α_1 and α_2 and α_3 subunits, respectively.

The benzodiazepine binding site of α_1 , α_2 , α_3 , and α_5 subunit-containing GABA_A receptors can be labeled in vivo using radiolabeled Ro 15-1788 (Goeders and Kuhar 1985; Potier et al. 1988a, 1988b; Persson et al. 1985). However, within the cerebellum, binding is predominantly to α_1 subunit-containing GABA_A receptors because although the cerebellum is the major site of α_6 subunit expression in the brain, Ro 15-1788 has a low affinity for this subpopulation of receptors. In addition, although [³H]Ro 15-1788 binds to the benzodiazepine site of GABA_A receptors containing an α_5 subunit, this population of receptors is expressed at relatively low levels throughout the brain as a whole, and in the cerebellum and spinal cord in particular (Fritschy and Mohler 1995; McKernan and Whiting 1996). Consequently, the binding of [³H]Ro 15-1788 to cerebellum and spinal cord in vivo represents binding to predominantly α_1 and α_2/α_3 subunit-containing GABA_A receptors, respectively.

The purpose of the present study was to establish whether the in vitro pharmacology of compounds relatively selective for GABA_A receptors containing an α_1 subunit, such as CL 218,872 and zolpidem, is reflected in vivo by differential occupancy in areas of the mouse CNS enriched in α_1 (cerebellum) versus α_2 and α_3 (spinal cord) subunit-containing receptors.

METHODS

Materials

[³H]Ro 15-1788 (70-87 Ci/mmol) was obtained from NEN Life Science Products (Stevenage, UK). CL 218,872 was a gift from Lederle, and diazepam, flunitrazepam, methyl 6,7-dimethoxy-4-ethyl- β -carboline-3-carboxylate (DMCM) and zolpidem were purchased from Research Biochemicals International (St. Albans, UK).

In Vitro Radioligand Binding

The affinities of compounds binding at the benzodiazepine binding site of different α subunit-containing human recombinant GABA_A receptors were measured essentially as described elsewhere (Hadingham et al. 1993). In brief, cells stably transfected with cDNA for the β_3 and γ_2 and various α subunits were harvested, and cell membranes prepared. Membranes (50 to 100 μ g protein) were incubated in the presence of varying concentrations of compound for 1 h at 4°C in assay buffer (10 mM potassium phosphate buffer containing 100 mM KCl, pH 7.4) containing [³H]Ro 15-1788 (concentration in assay = 1.8 nM for α_1 and α_2 and/or 1.0 nM α_3 and α_5 subunit-containing receptors) in a final assay volume of 0.5 ml. Non-specific binding was defined using 10 μ M flunitrazepam. The K_i values were calcu-

lated from the IC₅₀ value according to the Cheng-Prussosof equation (Cheng and Prussosof 1973).




In Vivo Binding of [³H]Ro 15-1788

The methods used were essentially those of Goeders and Kuhar (1985) as modified to include the separation

of membrane-bound from unbound radioactivity (Potier et al. 1988a, 1988b), although this separation of bound from free radioligand is not absolutely necessary (Facklam et al. 1992).

Time Course of Uptake of [³H]Ro 15-1788. [³H]Ro 15-1788 (70 to 87 Ci/mmol) was administered to male

Non-selective compounds

Compound	Structure	Ki, nM: β ₃ γ ₂ subunits plus			
		α ₁	α ₂	α ₃	α ₅
Diazepam		14	20	15	11
Flunitrazepam		2.2	2.5	4.5	2.1
DMCM*		7.1	8.2	5.8	9.5

α₁ selective compounds



Compound	Structure	Ki, nM: β ₃ γ ₂ subunits plus			
		α ₁	α ₂	α ₃	α ₅
CL-218,872		57	1960	1160	560
Zolpidem		27	160	380	>10,000

Figure 1. Affinities of compounds used for in vivo binding studies. *DMCM = Methyl 6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate. Ki's were established using stably transfected cells expressing β₃γ₂ plus α₁, α₂, α₃, or α₅ GABA_A receptor subunits. Radioligand used was [³H]Ro 15-1788.

Swiss-Webster mice (26 to 30 g) by tail vein injection (5 μ l/g of a 10 μ Ci/ml saline stock solution, equivalent to 1.5 μ Ci [3 H]Ro 15-1788/30 g mouse). Mice were then killed at varying times (0.5 to 30 min) later, and the whole brain was removed, weighed, and rapidly homogenized in 10 volumes of ice-cold buffer (10 mM potassium phosphate buffer containing 100 mM KCl, pH 7.4). Aliquots of homogenate (200 μ l) were either added directly to scintillation vials (total radioactivity; i.e., unbound and membrane-bound) or were filtered over Whatman GF/B filters (membrane-bound radioactivity). These were rapidly washed with 10 ml of ice-cold buffer, following which the filters were placed in vials, scintillation fluid was added, and radioactivity was measured using a scintillation counter.

Inhibition of In Vivo [3 H]Ro 15-1788 Binding. Compounds were made up as either a suspension in 0.5% carboxymethylcellulose (CMC) or in solution in 70% polyethyleneglycol 300 and were administered IP 30 min prior to killing; whereas, [3 H]Ro 15-1788 was given IV 3 min prior to killing. The cerebellum was then rapidly dissected from the brain, and the spinal cord was blown out of the spinal column using compressed air. Both tissues were weighed, rapidly homogenized, filtered, and counted as above.

Non-specific in vivo binding of [3 H]Ro 15-1788 was estimated by measuring the membrane-bound radioactivity in mice pretreated for 30 min with 30 mg/kg flunitrazepam. In these animals, the radioactivity in 200 μ l aliquots of homogenates of cerebellum and spinal cord (90 and 60 dpm, respectively) represented about 5% of the corresponding radioactivity seen in vehicle-treated animals (2,800 and 1,200 dpm, respectively).

RESULTS

Benzodiazepine-Site Ligand Affinities

In vitro, diazepam, flunitrazepam, and DMCM show no appreciable selectivity for the benzodiazepine binding

site of different α subunit-containing GABA_A receptors, with respective affinities across different recombinant GABA_A receptors in the region of 10 to 20 nM, 2 to 5 nM, and 5 to 10 nM (Figure 1). In contrast, CL 218,872 and zolpidem had affinities for the α_1 subunit-containing GABA_A receptor of 57 and 27 nM, which represented a 6 to 34-fold and 14 to 20-fold selectivity for α_1 versus α_2 - and α_3 -subunit-containing GABA_A receptors for CL 218,872 and zolpidem, respectively.

Time Course of In Vivo [3 H]Ro 15-1788 Binding

Figure 2 shows the distribution of total (homogenate) and membrane-bound (filtered and washed homogenate) [3 H]Ro 15-1788 at different times after IV injection. The time course of total and membrane-bound [3 H]Ro 15-1788 were very similar, with radioactivity rapidly entering the brain (within 3 min) and then being cleared from the brain with a *to.5* of around 8 min. Because maximal binding to whole brain membranes was observed after 3 min in all subsequent experiments, [3 H]Ro 15-1788 was administered 3 min prior to killing.

Reduction of In Vivo [3 H]Ro 15-1788 Binding by Nonselective Ligands

Figure 3 shows the reduction of in vivo [3 H]Ro 15-1788 binding from the cerebellum and spinal cord produced by the nonselective compounds diazepam, flunitrazepam, and DMCM. All these compounds showed a comparable reduction in in vivo [3 H]Ro 15-1788 binding (i.e., occupancy) in areas enriched in α_1 -subunit- (cerebellum) and α_2/α_3 -subunit-containing (spinal cord) GABA_A receptors.

The dose required to produce a 50% reduction in in vivo binding of cerebellar and spinal cord [3 H]Ro 15-1788 was around 0.2 to 0.3 mg/kg for flunitrazepam, 2 mg/kg for diazepam and 10 mg/kg for DMCM. However, the potency of these compounds was not related solely to their affinity. For example, diazepam has




Figure 2. Time course for the distribution of [3 H]Ro 15-1788 in homogenates of whole brain of mice killed at various times after IV injection of radioligand. Total counts (Δ) represent radioactivity in aliquots of unfiltered homogenate; whereas, membrane-bound counts (\blacktriangle) were obtained following filtration of aliquots of homogenate over Whatman GF/B glass fiber filters. Values shown represent means \pm SEM ($n = 6$ /group). Based on these data, an interval of 3 min after radioligand injection was chosen as the time after which maximal membrane-bound [3 H]Ro 15-1788 was achieved.




Figure 3. The binding of [³H]Ro 15-1788 to mouse cerebellum (●) and spinal cord (○) membranes after IP injections of vehicle or various doses of the nonselective compounds diazepam, flunitrazepam, or DMCM. Values are expressed as a percentage of binding relative to vehicle-treated animals (vehicle = carboxymethylcellulose for diazepam and flunitrazepam or 70% polyethyleneglycol for DMCM) and are shown as means ± SEM (*n* = 4-8/group).

lower affinity for the different GABA_A receptor subtypes than DMCM yet is fivefold more potent in vivo.

Reduction of In Vivo [³H]Ro 15-1788 Binding by α_1 -Selective Ligands

In contrast to nonselective compounds, the α_1 -selective compounds CL 218,872 and zolpidem produced a

greater reduction of in vivo [³H]Ro 15-1788 binding (i.e., occupancy) in the α_1 subunit-enriched cerebellum as compared to the predominantly α_2/α_3 subunit-containing spinal cord (Figure 4). Thus, the ID₅₀ values for the inhibition of cerebellum and spinal cord [³H]Ro 15-1788 binding were 4.5 and 12 mg/kg for CL 218,872 and 10 and >30 mg/kg for zolpidem, respectively. Again, there was no relationship between in vitro affinity and in vivo potency, with CL 218,872 being around twice as potent as zolpidem at displacing in vivo [³H]Ro 15-1788 binding from cerebellum (α_1 receptors), despite having twofold lower affinity for α_1 -containing receptors in vitro (affinities for CL 218,872 and zolpidem = 57 and 27 nM, respectively).

The relatively flat displacement curve for zolpidem in the spinal cord (Figure 3) is comparable to that seen in the mouse hippocampus (Benavides et al. 1988) and rat spinal cord (Benavides et al. 1992), and presumably, it reflects the heterogeneity of GABA_A receptors in these regions in contrast to the relatively homogeneous population of α_1 subunit-containing benzodiazepine binding sites associated with cerebellar GABA_A receptors.

DISCUSSION

The peak of both total and membrane-bound radioactivity was found to be 3 minutes after IV administration, in agreement with previous studies showing that [³H]benzodiazepines rapidly enter the brain (Goeders and Kuhar 1985; Ciliax et al. 1986; Potier et al. 1988b). The fact that more than 75% of the radioactivity in the brain is membrane bound suggests that the majority of [³H]Ro 15-1788 that gets into the brain is available for binding to the receptor and is not sequestered in pools unavailable for receptor binding. This is consistent with the low levels of nonspecific binding (<5%) as defined by doses of flunitrazepam that saturate the binding site and is in agreement with previous work (Potier et al. 1988a; Facklam et al. 1992). Taken together, these data demonstrate the utility of [³H]Ro 15-1788 as a radioligand with which to study benzodiazepine binding sites in vivo (Goeders and Kuhar 1985; Potier et al. 1988b).

The nonselective compounds diazepam, flunitrazepam, and DMCM, all of which have comparable affinities at different α subunit-containing GABA_A receptors, had essentially the same ID₅₀ for the displacement of [³H]Ro 15-1788 in cerebellum and spinal cord (Figure 3). A similar lack of regional selectivity for diazepam and flunitrazepam has been reported previously in various regions of the mouse (Potier et al. 1988b) and rat (Benavides et al. 1992) CNS. Moreover, the ID₅₀ for flunitrazepam of 0.2 to 0.3 mg/kg is in good agreement with previous published values of 0.17 mg/kg (Benavides et al. 1988) and 0.5 mg/kg (Potier et al. 1988b).




Figure 4. The binding of [^3H]Ro 15-1788 to mouse cerebellum (●) and spinal cord (○) membranes after IP injections of vehicle or various doses of the α_1 -selective compounds CL 218,872 and zolpidem. Values are expressed as a percentage of binding relative to vehicle-treated animals (vehicle = 70% polyethyleneglycol for CL 218,872 or carboxymethylcellulose for zolpidem) and are shown as means \pm SEM ($n = 4\text{--}8$ /group).

However, the ID_{50} for diazepam observed in the present study (2 mg/kg) is appreciably lower than previous estimates (10 mg/kg, Benavides et al. 1988).

Concerning α_1 selective compounds, the *in vitro* selectivity of CL 218,872 and zolpidem for α_1 versus α_2 and α_3 subunit-containing recombinant GABA_A receptors (Figure 1) was reflected by a preferential *in vivo* occupancy of cerebellum versus spinal cord (α_1 and α_2/α_3 subunit-containing tissues, respectively) benzodiazepine binding sites. Thus, lower doses of these α_1 -selective compounds were required to inhibit 50% of the *in vivo* binding of [^3H]Ro 15-1788 in cerebellum compared to spinal cord. A comparable selectivity of *in vivo* binding has also been observed in mouse cerebellum versus cortex or hippocampus (Potier et al. 1988b) and in rat cerebellum versus spinal cord (Benavides et al. 1992). In addition, autoradiographic studies of *in vivo* [^3H]Ro 15-1788 binding showed that the ID_{50} of zolpidem in a number of α_1 subunit-containing brain regions was appreciably lower than in regions with a more heterogeneous distribution of GABA_A receptor subtypes (Benavides et al. 1988).

Given the differences in drug formulation and dosing route between studies, the ID_{50} values for the displacement of *in vivo* [^3H]Ro 15-1788 binding in the cerebellum and spinal cord by CL 218,872 (4.5 and 12 mg/kg, respectively) and zolpidem (10 and >30 mg/kg, respectively) agree reasonably well with values reported previously for CL 218,872 in the mouse cerebellum (12 mg/kg; Potier et al. 1988b) and for zolpidem in autoradiographic analysis of mouse cerebellum (3.6 mg/kg; Benavides et al. 1988). This degree of selectivity is also observed in the rat where respective ID_{50} values for cerebellum and spinal cord were 6 and 19 mg/kg for CL 218,872 and 7 and >100 mg/kg for zolpidem (Benavides et al. 1992), although direct comparisons between effective doses in mice and rats is complicated by the possible species differences in pharmacokinetics (e.g., bretazenil, Martin et al. 1988).

It should be noted that the differences in the cerebellum and spinal cord ID_{50} values for the reduction in *in vivo* [^3H]Ro 15-1788 binding by CL 218,872 and zolpidem are generally less than the α_1 selectivity of these compounds *in vitro*. For example, CL 218,872 had ID_{50} values of 4.5 and 12 mg/kg—an *in vivo* selectivity of less than threefold—whereas, the affinity of this compound at α_1 subunit containing receptors *in vitro* is 20- and 35-fold higher than for α_2 and α_3 subunit-containing receptors, respectively. It is possible that this difference between *in vitro* affinity and *in vivo* potency could be attributable to different drug levels in the cerebellum and spinal cord. However, levels of zolpidem did not differ in rat cerebellum and spinal cord (Benavides et al. 1992), although this does not preclude the possibility of regional variations in CL 218,872 levels. The reason for this discrepancy between *in vitro* affinity and *in vivo* potency at α_1 versus α_2/α_3 receptors is unclear but underscores the need to establish *in vivo* occupancy of subtype selective compounds to rationalize the behavioral properties of such drugs.

Compounds acting at the benzodiazepine site of the GABA_A receptor produce a range of behavioral effects. The identification of subtypes of the GABA_A receptor with distinct pharmacological and structural properties along with discrete neuroanatomical localizations has led to the hypothesis that compounds that selectively interact with only some of these subtypes might possess only part of the range of effects associated with the non-selective benzodiazepines (Doble and Martin 1992). In addition to the *in vivo* occupancy, a further factor to be considered in understanding the mechanisms underlying the behavioral properties of a compound is the intrinsic efficacy of that compound (Facklam et al. 1992). Thus, for example, although compounds such as CL 218,872 and zolpidem selectively interact with the benzodiazepine site of α_1 subunit-containing GABA_A receptors, their different efficacies (partial and full agonists, respectively) results in distinct behavioral profiles

(Lüddens et al. 1995). In this respect, the inhibition of in vivo binding of [³H]benzodiazepines has proved to be crucial in unraveling the relationships between the degree of receptor occupancy required by compounds of varying intrinsic efficacies to produce distinct behavioral effects (Duka et al. 1979; Benavides et al. 1988, 1992; Facklam et al. 1992; Giusti et al. 1993; Martin et al. 1993; Jones et al. 1994).

The problems of interpreting behavioral data in terms of receptor occupancy and intrinsic efficacy is given an added dimension when considering attributing distinct behavioral properties to compounds that selectively interact with particular GABA_A receptor subtypes. In this regard, the fact that the occupancy of benzodiazepine binding sites in regions expressing different GABA_A receptor populations reflects their in vitro binding affinity suggests that the displacement of in vivo [³H]Ro 15-1788 binding in cerebellum and spinal cord should prove to be a valuable tool in unraveling the complexities of the behavioral profiles of α_1 or α_2/α_3 subtype-selective compounds.

REFERENCES

- Benavides J, Peny B, Dubois A, Perrault G, Morel E, Zivkovic B, Scatton B (1988): In vivo interaction of zolpidem with central benzodiazepine (BZD) binding sites (as labeled by [³H]Ro 15-1788) in the mouse brain. Preferential affinity of zolpidem for the ω_1 (BZD₁) subtype. *J Pharm Expt Ther* 245:1033–1041
- Benavides J, Peny B, Durand A, Arbilla S, Scatton B (1992): Comparative in vivo and in vitro regional selectivity of central ω (benzodiazepine) site ligands in inhibiting [³H]flumazenil binding in the rat central nervous system. *J Pharmacol Expt Ther* 263:884–896
- Cheng YC, Prussoff WH (1973): Relationship between the inhibition constant (K_i) and the concentration of inhibitor that causes 50% inhibition (IC_{50}) of an enzymatic reaction. *Biochem Pharmacol* 22:3099–3108
- Ciliax BJ, Penney Jr JB, Young AB (1986): In vivo [³H]flunitrazepam binding: Imaging of receptor regulation. *J Pharmacol Expt Ther* 238:749–757
- Davies PA, Hanna MC, Hales TG, Kirkness EF (1997): Insensitivity to anaesthetic agents conferred by a class of GABA_A receptor subunit. *Nature* 385:820–823
- Doble A, Martin IL (1992): Multiple benzodiazepine receptors: No reason for anxiety. *Trends Pharmacol Sci* 13:76–81
- Duka T, Höllt V, Herz A (1979): In vivo receptor occupancy by benzodiazepines and correlation with the pharmacological effect. *Brain Res* 179:147–156
- Facklam M, Schoch P, Haefely WE (1992): Relationship between benzodiazepine receptor occupancy and functional effects in vivo of four ligands of differing intrinsic efficacies. *J Pharmacol Expt Ther* 261:1113–1121
- Fritschy J-M, Mohler H (1995): GABA_A-receptor heterogeneity in the adult rat brain: Differential regional and cellular distribution of seven major subunits. *J Comp Neurol* 359:154–194
- Giusti P, Ducic I, Puia G, Arban R, Walser A, Guidotti A, Costa E (1993): Imidazenil: A new partial positive allosteric modulator of γ -aminobutyric acid (GABA) action at GABA_A receptors. *J Pharmacol Expt Ther* 266:1018–1028
- Goeders NE, Kuhar MJ (1985): Benzodiazepine receptor binding in vivo with [³H]-Ro 15-1788. *Life Sci* 37:345–355
- Hadingham KL, Wingrove P, Le Bourdelles B, Palmer KJ, Ragan CL, Whiting PJ (1993): Cloning of cDNA sequences encoding human α_2 and α_3 γ -aminobutyric acid_A receptor subunits and characterization of the benzodiazepine pharmacology of recombinant α_1 -, α_2 -, α_3 -, and α_5 -containing human γ -aminobutyric acid_A receptors. *Mol Pharmacol* 43:970–975
- Johnston GAR (1996): GABA_C receptors: Relatively simple transmitter-gated ion channels? *Trends Pharmacol Sci* 17:319–323
- Jones GH, Schneider C, Schneider HH, Seidler J, Cole BJ, Stephens DN (1994): Comparison of several benzodiazepine receptor ligands in two models of anxiolytic activity in the mouse: An analysis based on fractional receptor occupancies. *Psychopharmacology* 114:191–199
- Langer SZ, Arbilla S (1988): Imidazopyridines as a tool for the characterization of benzodiazepine receptors: A proposal for a pharmacological classification as omega receptor subtypes. *Pharmacol Biochem Behav* 29:763–766
- Lüddens H, Korpi ER, Seeburg PH (1995): GABA_A/benzodiazepine receptor heterogeneity: Neurophysiological implications. *Neuropharmacology* 34:245–254
- Martin JR, Pieri L, Bonetti EP, Schaffner R, Burkard WP, Cumin R, Haefely WE (1988): Ro 16-6028: A novel anxiolytic acting as a partial agonist in the benzodiazepine receptor. *Pharmacopsychiatry* 21:360–362
- Martin JR, Schoch P, Jenck F, Moreau J-L, Haefely WE (1993): Pharmacological characterization of benzodiazepine receptor ligands with intrinsic efficacies ranging from high to zero. *Psychopharmacology* 111:415–422
- McKernan RM, Whiting PJ (1996): Which GABA_A-receptor subtypes really occur in the brain? *Trends Neurosci* 19:139–143
- Persson A, Ehrin E, Eriksson L, Fade L, Hedstrom C-G, Litton J-E, Mindus P, Sedvall G (1985): Imaging of ¹¹C-labeled Ro 15-1788 binding to benzodiazepine receptors in human brain by positron emission tomography. *J Psychiatr Res* 4:609–622
- Potier M-C, Prado de Carvalho L, Dodd RH, Besselievre R, Rossier J (1988a): In vivo binding of β -carbolines in mice: Regional differences and correlation of occupancy to pharmacological effects. *Mol Pharmacol* 34:124–128
- Potier M-C, Prado de Carvalho L, Dodd RH, Brown CL, Rossier J (1988b): In vivo binding of (³H)Ro 15-1788 in mice: Comparison with the in vivo binding of (³H)flunitrazepam. *Life Sci* 43:1287–1296
- Rabow LE, Russek SJ, Farb DH (1995): From ion currents to genomic analysis: Recent advances in GABA_A receptor research. *Synapse* 21:189–274
- Sieghart W (1995): Structure and pharmacology of γ -aminobutyric acid_A receptor subtypes. *Pharmacol Rev* 47: 181–234

- Stephenson FA (1995): The GABA_A receptors. *Biochem J* 310:1–9
- Villiger JW (1984): CL 218,872 binding to benzodiazepine receptors in rat spinal cord: Modulation by γ -aminobutyric acid and evidence for receptor heterogeneity. *J Neurochem* 43:903–905
- Watanabe Y, Khatami S, Shibuya T, Salafsky B (1985): Ontogenic properties of benzodiazepine receptor subtypes in the rat spinal cord. *Eur J Pharmacol* 109:307–309
- Whiting PJ, McAllister G, Vasilatis D, Bonnert TP, Heavens RP, Smith DW, Hewson L, O'Donnell R, Rigby MR, Sirinathsinghji DJS, Marshall G, Thompson SA, Wafford KA (1997): Neuronally restricted RNA splicing regulates the expression of a novel GABA_A receptor subunit conferring atypical functional properties. *J Neurosci* 17:5027–5037
- Wisden W, Gundlach AL, Barnard EA, Seeburg PH, Hunt SP (1991): Distribution of GABA_A receptor subunit mRNAs in rat lumbar spinal cord. *Mol Brain Res* 10:179–183
- Wisden W, Laurie DJ, Monyer H, Seeburg PH (1992): The distribution of 13 GABA_A receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. *J Neurosci* 12:1040–1062